FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2554771773> ?p ?o ?g. }

• W2554771773 endingPage "1848.e10" @default.
• W2554771773 startingPage "1840" @default.
• W2554771773 abstract "BackgroundThe SQ house dust mite (HDM) sublingual immunotherapy (SLIT) tablet has been approved in 11 European countries and Japan for patients with HDM-induced respiratory allergic disease.ObjectiveThis trial was conducted to confirm the efficacy and safety of the SQ HDM SLIT tablet in Japanese patients with moderate-to-severe HDM-induced allergic rhinitis (AR).MethodsThe trial was a randomized, double-blind, placebo-controlled trial including 946 Japanese adults and adolescents (12-64 years). Subjects were randomly assigned to daily treatment with the SQ HDM SLIT tablet at a dose of 10,000 Japanese allergy units (JAU) or 20,000 JAU or to placebo (1:1:1). The primary end point was the total combined rhinitis score (TCRS), which is composed of AR symptom and medication scores during the efficacy evaluation period. Symptom and medication scores of AR and conjunctivitis, rhinitis quality of life, and symptom-free and symptom-severe days were evaluated as secondary end points.ResultsAnalysis of the primary end point demonstrated statistically significant reductions in TCRSs of 1.15 (22%, P < .001) in the 10,000-JAU group and 0.99 (19%, P < .001) in the 20,000-JAU group compared with the placebo group. The statistically significant treatment effect was evident from 12 weeks of treatment onward. All secondary end points, except AR medication score, were statistically significant in favor of active treatment compared with placebo. Post hoc analysis of TCRSs in adolescents showed the same efficacy as in adults (P < .05). The treatment was well tolerated by both adults and adolescents.ConclusionThe trial confirmed the efficacy and safety profile of the SQ HDM SLIT tablet in Japanese adult and adolescent patients with moderate-to-severe HDM-induced AR. These data support the robust efficacy and safety profile of previously reported European data. The SQ house dust mite (HDM) sublingual immunotherapy (SLIT) tablet has been approved in 11 European countries and Japan for patients with HDM-induced respiratory allergic disease. This trial was conducted to confirm the efficacy and safety of the SQ HDM SLIT tablet in Japanese patients with moderate-to-severe HDM-induced allergic rhinitis (AR). The trial was a randomized, double-blind, placebo-controlled trial including 946 Japanese adults and adolescents (12-64 years). Subjects were randomly assigned to daily treatment with the SQ HDM SLIT tablet at a dose of 10,000 Japanese allergy units (JAU) or 20,000 JAU or to placebo (1:1:1). The primary end point was the total combined rhinitis score (TCRS), which is composed of AR symptom and medication scores during the efficacy evaluation period. Symptom and medication scores of AR and conjunctivitis, rhinitis quality of life, and symptom-free and symptom-severe days were evaluated as secondary end points. Analysis of the primary end point demonstrated statistically significant reductions in TCRSs of 1.15 (22%, P < .001) in the 10,000-JAU group and 0.99 (19%, P < .001) in the 20,000-JAU group compared with the placebo group. The statistically significant treatment effect was evident from 12 weeks of treatment onward. All secondary end points, except AR medication score, were statistically significant in favor of active treatment compared with placebo. Post hoc analysis of TCRSs in adolescents showed the same efficacy as in adults (P < .05). The treatment was well tolerated by both adults and adolescents. The trial confirmed the efficacy and safety profile of the SQ HDM SLIT tablet in Japanese adult and adolescent patients with moderate-to-severe HDM-induced AR. These data support the robust efficacy and safety profile of previously reported European data." @default.
• W2554771773 created "2016-11-30" @default.
• W2554771773 creator A5011396629 @default.
• W2554771773 creator A5012543365 @default.
• W2554771773 creator A5030253468 @default.
• W2554771773 creator A5042510805 @default.
• W2554771773 creator A5072767964 @default.
• W2554771773 creator A5075479619 @default.
• W2554771773 creator A5087150619 @default.
• W2554771773 date "2017-06-01" @default.
• W2554771773 modified "2023-10-05" @default.
• W2554771773 title "Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite–induced allergic rhinitis" @default.
• W2554771773 cites W1132113666 @default.
• W2554771773 cites W1986921101 @default.
• W2554771773 cites W1990363412 @default.
• W2554771773 cites W1997729446 @default.
• W2554771773 cites W2003307682 @default.
• W2554771773 cites W2005107727 @default.
• W2554771773 cites W2010998136 @default.
• W2554771773 cites W2028803867 @default.
• W2554771773 cites W2033573844 @default.
• W2554771773 cites W2055685990 @default.
• W2554771773 cites W2060328264 @default.
• W2554771773 cites W2062758156 @default.
• W2554771773 cites W2113389712 @default.
• W2554771773 cites W2117139404 @default.
• W2554771773 cites W2141856163 @default.
• W2554771773 cites W2142388937 @default.
• W2554771773 cites W2142589482 @default.
• W2554771773 cites W2154185834 @default.
• W2554771773 cites W2164600165 @default.
• W2554771773 cites W2167170367 @default.
• W2554771773 cites W2302277303 @default.
• W2554771773 cites W2344044328 @default.
• W2554771773 doi "https://doi.org/10.1016/j.jaci.2016.09.043" @default.
• W2554771773 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27864024" @default.
• W2554771773 hasPublicationYear "2017" @default.
• W2554771773 type Work @default.
• W2554771773 sameAs 2554771773 @default.
• W2554771773 citedByCount "81" @default.
• W2554771773 countsByYear W25547717732016 @default.
• W2554771773 countsByYear W25547717732017 @default.
• W2554771773 countsByYear W25547717732018 @default.
• W2554771773 countsByYear W25547717732019 @default.
• W2554771773 countsByYear W25547717732020 @default.
• W2554771773 countsByYear W25547717732021 @default.
• W2554771773 countsByYear W25547717732022 @default.
• W2554771773 countsByYear W25547717732023 @default.
• W2554771773 crossrefType "journal-article" @default.
• W2554771773 hasAuthorship W2554771773A5011396629 @default.
• W2554771773 hasAuthorship W2554771773A5012543365 @default.
• W2554771773 hasAuthorship W2554771773A5030253468 @default.
• W2554771773 hasAuthorship W2554771773A5042510805 @default.
• W2554771773 hasAuthorship W2554771773A5072767964 @default.
• W2554771773 hasAuthorship W2554771773A5075479619 @default.
• W2554771773 hasAuthorship W2554771773A5087150619 @default.
• W2554771773 hasBestOaLocation W25547717731 @default.
• W2554771773 hasConcept C126322002 @default.
• W2554771773 hasConcept C142724271 @default.
• W2554771773 hasConcept C168563851 @default.
• W2554771773 hasConcept C199215989 @default.
• W2554771773 hasConcept C203014093 @default.
• W2554771773 hasConcept C203092338 @default.
• W2554771773 hasConcept C204787440 @default.
• W2554771773 hasConcept C207480886 @default.
• W2554771773 hasConcept C27081682 @default.
• W2554771773 hasConcept C2777037608 @default.
• W2554771773 hasConcept C2778166374 @default.
• W2554771773 hasConcept C2779711295 @default.
• W2554771773 hasConcept C2780510475 @default.
• W2554771773 hasConcept C42219234 @default.
• W2554771773 hasConcept C54355233 @default.
• W2554771773 hasConcept C59822182 @default.
• W2554771773 hasConcept C71924100 @default.
• W2554771773 hasConcept C86803240 @default.
• W2554771773 hasConceptScore W2554771773C126322002 @default.
• W2554771773 hasConceptScore W2554771773C142724271 @default.
• W2554771773 hasConceptScore W2554771773C168563851 @default.
• W2554771773 hasConceptScore W2554771773C199215989 @default.
• W2554771773 hasConceptScore W2554771773C203014093 @default.
• W2554771773 hasConceptScore W2554771773C203092338 @default.
• W2554771773 hasConceptScore W2554771773C204787440 @default.
• W2554771773 hasConceptScore W2554771773C207480886 @default.
• W2554771773 hasConceptScore W2554771773C27081682 @default.
• W2554771773 hasConceptScore W2554771773C2777037608 @default.
• W2554771773 hasConceptScore W2554771773C2778166374 @default.
• W2554771773 hasConceptScore W2554771773C2779711295 @default.
• W2554771773 hasConceptScore W2554771773C2780510475 @default.
• W2554771773 hasConceptScore W2554771773C42219234 @default.
• W2554771773 hasConceptScore W2554771773C54355233 @default.
• W2554771773 hasConceptScore W2554771773C59822182 @default.
• W2554771773 hasConceptScore W2554771773C71924100 @default.
• W2554771773 hasConceptScore W2554771773C86803240 @default.
• W2554771773 hasFunder F4320316817 @default.
• W2554771773 hasIssue "6" @default.
• W2554771773 hasLocation W25547717731 @default.
• W2554771773 hasLocation W25547717732 @default.
• W2554771773 hasOpenAccess W2554771773 @default.

• next